Losartan Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

The Losartan Market was valued at USD 728.50 Million in 2024, and is expected to reach USD 898.16 Million by 2030, rising at a CAGR of 3.75%. Losartan, an angiotensin II receptor blocker (ARB), is extensively prescribed for managing hypertension, heart failure, and diabetic nephropathy. Its clinical efficacy, affordability, and safety profile have contributed to its broad utilization across diverse global healthcare systems. The growing burden of lifestyle-related illnesses such as obesity, hypertension, and type 2 diabetes - especially among aging populations - has significantly bolstered demand for antihypertensive medications like losartan.

Additionally, increasing public awareness around chronic disease prevention, the growth of the generic pharmaceutical sector, and the promotion of accessible treatments are further propelling market expansion. However, challenges such as product recalls linked to contamination and sustained pricing pressures due to intense generic competition have tempered profitability for some manufacturers. Despite these constraints, losartan remains a mainstay in cardiovascular therapy across both mature and emerging markets.

Key Market Drivers

Growth in Healthcare Industry

The robust expansion of the global healthcare sector, with annual sales surpassing USD 4 trillion, continues to drive the growth of the losartan market. Key segments such as pharmaceuticals and biotechnology account for over USD 850 billion, while diagnostics and medical technology contribute more than USD 400 billion. As healthcare systems worldwide scale up to meet the rising prevalence of chronic conditions, there is heightened focus on early intervention and long-term management strategies for cardiovascular and renal diseases. This has elevated the demand for effective antihypertensive agents, with losartan positioned as a first-line option due to its efficacy in managing blood pressure and reducing the risk of stroke and kidney damage in diabetic patients. Increased healthcare spending, particularly in developing countries, along with broader access to generics, is further accelerating market growth.

Key Market Challenges

Disruption in Supply Chain

Supply chain disruptions pose a persistent challenge to the global losartan market, impacting the availability and timely distribution of both active pharmaceutical ingredients (APIs) and finished formulations. The production of losartan heavily depends on stable API sourcing, predominantly from manufacturing hubs in India and China. Any disruption caused by regulatory non-compliance, factory shutdowns, environmental restrictions, or geopolitical tensions can lead to delays and shortages. In addition, reliance on limited global suppliers creates bottlenecks, especially during periods of heightened demand. These interruptions not only affect drug availability but can also lead to price fluctuations, undermining supply chain resilience and complicating inventory management for manufacturers and healthcare providers alike.

Key Market Trends

Increasing Research into Combination Therapies

A growing trend shaping the losartan market is the increasing focus on fixed-dose combination therapies for the treatment of hypertension and related cardiovascular disorders. With the complexity of disease management rising, pharmaceutical companies are exploring synergistic formulations that combine losartan with complementary antihypertensive agents such as hydrochlorothiazide or amlodipine. These combination therapies aim to improve therapeutic outcomes, simplify dosing regimens, and boost patient adherence. Inspired by successful models in oncology and other chronic disease areas, this trend is supported by clinical data demonstrating enhanced efficacy and patient satisfaction. Fixed-dose combinations also offer pharmaceutical companies a pathway to differentiate their products in a competitive generic market, helping to extend product lifecycles and align with evolving clinical guidelines that prioritize combination treatment strategies.

Key Market Players

• Merck & Co. Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Novartis International AG
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceuticals Industries Ltd.
• Aurobindo Pharma Ltd.
• Torrent Pharmaceutical Ltd.
• Lupin Ltd.

Report Scope

In this report, the Global Losartan Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Losartan Market, By Source:

• Contract Manufacturing Organizations
• In-House

Losartan Market, By Application:

• Hypertension
• Stroke
• Diabetic Nephropathy
• Others

Losartan Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Losartan Market.

Available Customizations

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.